Consensus Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.4 ^USD	+3.34%		-10.05%	-61.32%

Apr. 26	AbbVie raises annual profit forecast on strong Skyrizi sales	RE
Apr. 12	Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	CI

Evolution of the average Target Price on Revance Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9de013d9c36b7eea2a.cWly2upSoBQkoH6D_0CP_fJNn1nl-4QhTKnfwwzi_k4.C0RFud0Lk1x3xgy3sQ65qIR_rRzdjONlG_-4mjTahjwHGDq-gQLSdX3kMw~46df82286e34c8a05f9d6f4eeb771ff1

Analyst Recommendations on Revance Therapeutics, Inc.

Goldman Sachs Adjusts Price Target on Revance Therapeutics to $9 From $8, Maintains Neutral Rating	Mar. 01	MT
Needham Cuts Price Target on Revance Therapeutics to $18 From $20, Maintains Buy Rating	Feb. 29	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating	Feb. 29	MT
Mizuho Securities Downgrades Revance Therapeutics to Neutral From Buy, Lowers Price Target to $9 From $16	Jan. 29	MT
Needham Cuts Price Target on Revance Therapeutics to $20 From $25, Maintains Buy Rating	Jan. 09	MT
Goldman Sachs Downgrades Revance Therapeutics to Neutral From Buy, Cuts Price Target to $8 From $30	Jan. 09	MT
Mizuho Adjusts Revance Therapeutics' Price Target to $16 From $35, Maintains Buy Rating	Nov. 22	MT
Piper Sandler Adjusts Revance Therapeutics' Price Target to $42 From $44, Maintains Overweight Rating	Nov. 09	MT
Needham Adjusts Revance Therapeutics Price Target to $25 From $35, Maintains Buy Rating	Nov. 09	MT
HC Wainwright Adjusts Revance Therapeutics' Price Target to $15 From $41, Keeps Buy Rating	Nov. 06	MT
Barclays Adjusts Revance Therapeutics' Price Target to $35 From $40, Maintains Overweight Rating	23-10-23	MT
Morgan Stanley Lowers Price Target on Revance Therapeutics to $12 From $25, Maintains Equalweight Rating	23-10-11	MT
Goldman Sachs Adjusts Revance Therapeutics' Price Target to $33 From $38, Keeps Buy Rating	23-09-21	MT
Piper Sandler Adjusts Price Target on Revance Therapeutics to $44 From $50, Maintains Overweight Rating	23-09-20	MT
Needham Adjusts Revance Therapeutics Price Target to $35 From $40, Maintains Buy Rating	23-09-20	MT
BNP Paribas Exane Upgrades Revance Therapeutics to Neutral From Underperform, Price Target is $20	23-08-16	MT
Morgan Stanley Adjusts Price Target on Revance Therapeutics to $25 From $26, Maintains Equal-Weight Rating	23-08-09	MT
Needham Adjusts Price Target on Revance Therapeutics to $40 From $44, Maintains Buy Rating	23-08-09	MT
HC Wainwright Adjusts Price Target on Revance Therapeutics to $41 From $48, Maintains Buy Rating	23-08-09	MT
Mizuho Securities Adjusts Revance Therapeutics Price Target to $35 From $33, Maintains Buy Rating	23-06-07	MT
HC Wainwright Adjusts Price Target on Revance Therapeutics to $48 From $42, Maintains Buy Rating	23-05-10	MT
Barclays Adjusts Price Target on Revance Therapeutics to $40 From $37, Maintains Overweight Rating	23-03-01	MT
Needham Adjusts Price Target on Revance Therapeutics to $40 From $38, Keeps Buy Rating	23-03-01	MT
Piper Sandler Adjusts Revance Therapeutics' Price Target to $40 From $29, Keeps Overweight Rating	23-01-31	MT
HC Wainwright Adjusts Revance Therapeutics' Price Target to $42 From $29, Keeps Buy Rating	23-01-26	MT